Bronchoalveolar lavage surfactant protein a, B, and d concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants.
Surfactant proteins (SPs) play an important role in surfactant metabolism and function. Understanding their relative contribution to clinical outcome remains incomplete. Exogenous surfactants differ in their SP content and physiologic effects. The aims of this study were to measure bronchoalveolar lavage (BAL) SP concentrations from preterm infants ventilated for respiratory distress syndrome and to assess their association with clinical outcome. Fifty preterm infants randomized to receive a natural or synthetic surfactant were lavaged each day for the first week and twice weekly thereafter using a standardized nonbronchoscopic technique. BAL SP-A, SP-B, and SP-D concentrations were measured using ELISA. Median BAL SP-A, SP-B, and SP-D concentrations for the whole cohort rose significantly during the first postnatal week (p < 0.05). SP-A concentration did not differ between outcome groups. BAL SP-B concentration rose significantly in lungs that were not supplemented with SP-B. Infants dying had significantly lower BAL SP-B concentrations on d 2 and 6 compared with survivors. BAL SP-D concentrations were significantly lower on d 2 and 3 among infants in supplemental oxygen on d 28 compared with those in air. BAL SP-A and SP-D concentrations did not differ significantly between infants randomized to receive a natural or synthetic surfactant. Lower BAL SP-B and SP-D but not SP-A concentrations were associated with worse clinical prognosis.
Beresford
Michael W
MW
Neonatal Unit, Liverpool Women's Hospital, UK. m_beresford@yahoo.com
Shaw
Nigel J
NJ
D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D011237:Predictive Value of Tests; D011379:Prognosis; D037662:Pulmonary Surfactant-Associated Protein A / Q000032:analysis / Q000493:pharmacokinetics; D037701:Pulmonary Surfactant-Associated Protein B / Q000032:analysis / Q000493:pharmacokinetics; D037663:Pulmonary Surfactant-Associated Protein D / Q000032:analysis / Q000493:pharmacokinetics; D037661:Pulmonary Surfactant-Associated Proteins / Q000032:analysis / Q000493:pharmacokinetics*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D015996:Survival Rate
D037662:Pulmonary Surfactant-Associated Protein A; D037701:Pulmonary Surfactant-Associated Protein B; D037663:Pulmonary Surfactant-Associated Protein D; D037661:Pulmonary Surfactant-Associated Proteins